Anti-ADH7 Antibody
- 产品详情
- 实验流程
Application
| WB, IF/IC |
|---|---|
| Primary Accession | P40394 |
| Reactivity | Human, Mouse, Rat, Pig, Mk |
| Host | Rabbit |
| Clonality | Polyclonal |
| Calculated MW | 41481 Da |
| Gene ID | 131 |
|---|---|
| Other Names | Alcohol dehydrogenase class 4 mu/sigma chain; Alcohol dehydrogenase class IV mu/sigma chain; Gastric alcohol dehydrogenase; Retinol dehydrogenase |
| Target/Specificity | KLH-conjugated synthetic peptide encompassing a sequence within the center region of human ADH7. The exact sequence is proprietary. |
| Dilution | WB~~WB (1/500 - 1/1000) IF/IC~~N/A |
| Format | Liquid in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.01% sodium azide. |
| Storage | Store at -20 °C.Stable for 12 months from date of receipt |
For Research Use Only. Not For Use In Diagnostic Procedures.
| Name | ADH7 (HGNC:256) |
|---|---|
| Function | Catalyzes the NAD-dependent oxidation of all-trans-retinol, alcohol, and omega-hydroxy fatty acids and their derivatives (PubMed:15369820, PubMed:16787387, PubMed:9600267). Oxidizes preferentially all trans-retinol, all-trans-4-hydroxyretinol, 9-cis- retinol, 2-hexenol, and long chain omega-hydroxy fatty acids such as juniperic acid (PubMed:15369820, PubMed:16787387, PubMed:9600267). In vitro can also catalyze the NADH-dependent reduction of all-trans- retinal and aldehydes and their derivatives (PubMed:15369820, PubMed:16787387, PubMed:9600267). Reduces preferentially all trans- retinal, all-trans-4-oxoretinal and hexanal (PubMed:15369820, PubMed:16787387). Catalyzes in the oxidative direction with higher efficiency (PubMed:15369820, PubMed:16787387). Therefore may participate in retinoid metabolism, fatty acid omega-oxidation, and elimination of cytotoxic aldehydes produced by lipid peroxidation (PubMed:15369820, PubMed:16787387, PubMed:9600267). |
| Cellular Location | Cytoplasm. |
| Tissue Location | Preferentially expressed in stomach. |
Research Areas
Application Protocols
Provided below are standard protocols that you may find useful for product applications.
REFERENCES
Farres J.,et al.Eur. J. Biochem. 224:549-557(1994).
Satre M.A.,et al.J. Biol. Chem. 269:15606-15612(1994).
Zgombic-Knight M.,et al.J. Biol. Chem. 270:4305-4311(1995).
Ota T.,et al.Nat. Genet. 36:40-45(2004).
Hillier L.W.,et al.Nature 434:724-731(2005).
终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。
如有疑问,联系:0512-88856768 tech-china@abcepta.com.
¥ 1,250.00
Cat# AP51719
















癌症的基本特征包括细胞增殖、血管生成、迁移、凋亡逃避机制和细胞永生等。找到癌症发生过程中这些通路的关键标记物和对应的抗体用于检测至关重要。
为您推荐一个泛素化位点预测神器——泛素化分析工具,可以为您的蛋白的泛素化位点作出预测和评分。
细胞自噬受体图形绘图工具为你的蛋白的细胞受体结合位点作出预测和评分,识别结合到自噬通路中的蛋白是非常重要的,便于让我们理解自噬在正常生理、病理过程中的作用,如发育、细胞分化、神经退化性疾病、压力条件下、感染和癌症。